Navigation Links
CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
Date:2/3/2010

VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE  CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2010 BIO CEO & Investor Conference.  Hosted by the Biotechnology Industry Organization (BIO), the conference will take place February 8-9 at the Waldorf=Astoria in New York.

Mr. Kersten's presentation will be on Tuesday, February 9th, at 1:30 p.m. EST.  The presentation will be webcast live with slides and archived until May 11, 2010.  The webcast can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2010/05209268.cfm.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine® is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S.™ technology platform.  This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu.  This investigational treatment is currently being tested in a clinical study at Johns Hopkins University.  The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

About The BIO CEO & Investor Conference

Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry.  The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry.  This years' conference will feature corporate presentations from more than 120 companies, workshops featuring leading experts on specific therapeutic and technology topics, plenary and panel sessions on timely business issues and industry trends, many opportunities to schedule one-on-one meetings, as well as numerous networking opportunities.  For more information, visit www.ceo.bio.org.

SOURCE CEL-SCI Corporation

RELATED LINKS
http://www.cel-sci.com

'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
2. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
3. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
6. CEL-SCI Expands H1N1 Flu Virus Work
7. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
8. CEL-SCI Posts New Corporate Presentation to Website
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Corporation Releases Letter to Shareholders
11. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):